QuidelOrtho (QDEL) Q4 2025 earnings review
Core Business Shines, but COVID Drag Persists
QuidelOrtho is successfully pivoting away from its pandemic reliance. While total revenue grew a modest 2% YoY to $724M, the core 'Labs' business accelerated to 8% growth, proving the underlying investment thesis is intact. However, the legacy impacts are still felt: Respiratory revenue fell 14% due to lower COVID testing, and the company posted a GAAP Net Loss of $131M. Management's cost-cutting is the unsung hero, delivering an Adjusted EBITDA margin of 21% despite the revenue mix shift. FY26 guidance projects a return to positive Free Cash Flow, signaling financial stabilization.
🐂 Bull Case
The Labs segment, which represents the company's future, accelerated to 8% growth (7% constant currency). Excluding the dying Donor Screening business, non-respiratory revenue grew 7% in constant currency. The thesis of a durable, recurring-revenue diagnostics utility is materializing.
Despite top-line volatility, FY25 Adjusted EBITDA margins landed at 22% (up 240bps YoY), meeting guidance. FY26 guidance calls for further expansion to ~23.3%, confirming that cost-saving initiatives are structural, not temporary.
🐻 Bear Case
FY25 Free Cash Flow was negative $(77)M, weighed down by ERP implementation costs and impairments. While FY26 guides for positive $120-160M, this is a thin buffer for a company carrying over $2.6B in total borrowings.
The company posted a massive FY25 GAAP Net Loss of $1.13B (driven by a Q3 impairment). Even in Q4, without massive impairments, the GAAP Net Loss was $131M. The gap between Adjusted EBITDA ($153M) and GAAP Net Loss suggests heavy adjustments and high non-cash costs persist.
⚖️ Verdict: ⚪
Neutral. The operational pivot is working—Labs growth is real and cost cuts are sticking. However, the balance sheet remains stretched with negative FY25 cash flow and high leverage. FY26 guidance is constructive, but execution on cash generation is now non-negotiable.
Key Themes
Labs Segment Acceleration
Accelerating. The Labs business is breaking out, posting 8.1% YoY reported growth in Q4, up from ~4% in previous quarters. This segment is the stabilizer against respiratory volatility. If this mid-to-high single-digit growth holds, QDEL re-rates as a stable MedTech compounder rather than a COVID stock.
Respiratory Revenue Decline
Decelerating. Respiratory revenue fell 14% YoY to $123M in Q4. While flu grew 6%, COVID demand continues to evaporate. This segment remains a drag on topline optics, obscuring the growth in the rest of the portfolio.
Free Cash Flow & Debt
Reversing. FY25 Free Cash Flow finished at negative $(77)M, driven by ERP investments and restructuring. With Total Borrowings at ~$2.65B, the company has no room for error. FY26 guidance projects a rebound to +$120-160M, which is critical for debt service and deleveraging.
Donor Screening Exit
The strategic exit from U.S. Donor Screening is painful now but necessary. Revenue collapsed 40% YoY in Q4 to just $11.8M. This headwind will likely persist through 2026 until the lap is complete, artificially suppressing total company growth rates.
CFO Transition
CFO Joseph Busky announced his retirement effective June 30, 2026. While an orderly transition is planned, C-suite turnover during a critical financial pivot (negative to positive cash flow) introduces execution risk.
Other KPIs
Stable. Margins held flat YoY (21.2% vs 21.2%) despite the revenue mix shift away from high-margin COVID testing. This demonstrates that cost-savings initiatives are effectively offsetting the loss of pandemic windfall profits.
Improved but still red. The loss narrowed from $(178)M in 24Q4. High amortization ($45M) and restructuring charges ($29M) continue to weigh on GAAP results, keeping the company in the red on a statutory basis.
Elevated. Long-term borrowings increased to $2.47B from $2.14B a year ago, while current portion decreased. With cash of only $170M, the leverage ratio remains a key monitorable.
Guidance
Accelerating. The midpoint ($2.8B) implies ~2.5% growth over FY25's $2.73B. This signals an end to the post-pandemic contraction phase.
Accelerating. Midpoint ($650M) implies ~9% growth vs FY25 ($597M). The implied margin expansion to ~23.3% suggests operating leverage is returning.
Reversing. A critical pivot from FY25's $(77)M burn. This metric is the single most important number in the guidance; failing to hit this would raise immediate liquidity alarms given the debt load.
Key Questions
Free Cash Flow Bridge
FY25 FCF was negative $77M. Can you walk us through the specific bridge to +$140M (midpoint) in FY26? How much of this is CapEx reduction vs. working capital unwind?
Labs Growth Sustainability
Labs growth accelerated to 8% in Q4. Was this driven by specific one-time instrument placements or capital budget flushes, or is this the new run-rate for the core business?
LEX Diagnostics Acquisition Status
The risk factors mention 'failure to acquire... LEX Diagnostics.' What is the current status of this deal, and does the FY26 guidance assume any contribution or integration costs from it?